The Cell and Gene Therapy group operates in the field of Advanced Therapy Medicinal Products. A major focus is the generation of dopaminergic neurons from induced pluripotent stem cells for Parkinson’s disease therapy, with particular emphasis on safety switch technology and optimized differentiation protocols. Another key area is the development of packaging cell lines to improve the efficiency and scalability of gene therapy vector production.
